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Abstract
OBJECTIVES: Aortic valve calciﬁcation and changes after transcatheter aortic valve implantation (TAVI) were speciﬁcally assessed by com-
puted tomography (CT). The main difference between TAVI and the conventional technique is the compression of the cusps of the calciﬁed
native valve against the aortic wall before implantation. The objective of this study was to quantify the segmented calciﬁcation in the area
of the basal annular plane before and after TAVI.
METHODS: The CT scans of 20 patients (13 male and 7 female; mean age: 82.9 ± 8.1 years) were assessed. The aortic valve calciﬁcation
was segmented; derived from this segmentation volume, mass and Hounsﬁeld units (HU)/density of the calciﬁcations on the annulus and
cusps before and after TAVI were evaluated. Pre- and postoperative data were compared regarding potential calciﬁcation loss and calciﬁca-
tion distances to the left and right coronary ostia.
RESULTS: Signiﬁcantly lower postprocedural mean volumes and masses for all cusps (P < 0.001) were found. The mean differences in the
volume for the non-coronary, right-coronary and left-coronary cusp were −156.8 ± 53.73, −155.5 ± 62.54 and −115 ± 57.53 mm3, respect-
ively, and differences in mass were −88.78 ± 29.48, −95.2 ± 39.27 and −71.56 ± 35.62 mg, respectively. Over all cusps, mean HU increased
after intervention [784.41 ± 92.5 HU (pre) and 818.63 ± 78.71 HU (post); P < 0.004]. In 80.03% of all cusps, calciﬁcation loss was found; all
patients were affected. Signiﬁcantly lower (P < 0.047) postprocedural mean distances were found from the left and right coronary ostia to
the next calciﬁcation point.
CONCLUSIONS: Our results show a signiﬁcant loss of calciﬁcation in all patients after TAVI, with a reduction in the calciﬁcation distances to
the coronary ostia and the compression of calciﬁcation in the area of the device landing zone. The clinical implications of this ﬁnding need
to be investigated further.
Keywords: Aortic root • Aortic valve repair • Aortic valve replacement • Valve calciﬁcation
INTRODUCTION
With the increase in average life expectancy in the western com-
munity, the occurrence of degenerative aortic stenosis is continu-
ously increasing and has reached a prevalence of 4.8% in patients
>75 years old [1, 2]. Conventional surgical aortic valve replacement
(AVR) has been performed for decades and still represents the
standard of care. Improvements in surgical techniques have led to
a reduction of morbidity and mortality rates to 2.3% after AVR [3].
Transcatheter aortic valve implantation (TAVI) has evolved as an
alternative treatment technique for patients with severe aortic
stenosis, who do not qualify for AVR owing to either multiple co-
morbidities or high surgical risk [4]. The PARTNER B trial, a rando-
mized trial analysing the outcome of TAVI in comparison to
optimal medical therapy in inoperable patients, demonstrated an
improvement of survival of 20% at 1 year, as well as a signiﬁcant
decrease of symptoms in the TAVI group [5]. Since the ﬁrst percu-
taneous transcatheter aortic valve implantation performed in
2002, despite the lack of evidence, the use of TAVI is increasingly
shifting toward younger and operable patients [6].
While TAVI is clearly less invasive than AVR and does not
require sternotomy and the use of cardiopulmonary bypass,
major complications after TAVI include cerebrovascular events,
acute kidney injury, an incidence of paravalvular leakage and post-
operative atrioventricular (AV) blockages requiring pacemaker im-
plantation [7–10]. The incidence of stroke or transient ischaemic
attacks after TAVI ranging from 0.6 to 6% [1]. Rodés-Cabau demon-
strated a high rate of silent cerebral ischaemic lesions in diffusion-
weighted magnetic resonance imaging ranging from 66 to 71% in-
dependent of a transfemoral or transapical approach. The inci-
dence of coronary artery obstruction during or after TAVI is
reported between 0.4 and 4.1% [11]. The incidence of AV block,
© The Author 2013. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved.
O
R
IG
IN
A
L
A
R
TI
C
LE
Interactive CardioVascular and Thoracic Surgery (2013) 1–6 ORIGINAL ARTICLE – ADULT CARDIAC
doi:10.1093/icvts/ivt432
 Interactive CardioVascular and Thoracic Surgery Advance Access published October 8, 2013
with the consecutive need for a pacemaker, is up to ﬁve times
higher after TAVI than after AVR [12, 13]. The main difference dis-
tinguishing TAVI from AVR is the lack of removal of the native
aortic valve and its calciﬁcations. This can lead to additional forces
on the surrounding tissue after valve expansion, including the area
of the AV node and the bundle of His, because these anatomical
regions are near to the area of the right coronary aortic leaﬂet
[14, 15].
The objective of this study was the quantiﬁcation of the seg-
mented calciﬁcation in the area of the basal annular plane before
and after TAVI, with a particular focus on changes in mass, volume
and density [Hounsﬁeld units (HU)], and to determine the loss of
calciﬁcation. In addition, the displacement of calciﬁed debris
towards the coronary ostia, as well as the compression of calciﬁed
lesions into the sensitive anatomical area of the cardiac conduc-
tion system, was evaluated.
MATERIALS ANDMETHODS
Study population
We retrospectively included 20 patients (13 men and 7 women;
mean age: 82.9 ± 8.1 years), who underwent TAVI from June 2008
until July 2011. The preoperative risk as expressed by the mean lo-
gistic EuroSCORE was 21.4%. The indication for TAVI was approved
by the local heart team and in concordance with the recent con-
sensus statement [16]. All patients had a clinical pre- and post-
operative contrast-enhanced computed tomography (CT) scan
with ECG gating. The postoperative CT examination was a median
of 16 days (range 6–46 days) after the procedure. Ethical approval
for this retrospective study was obtained from the institutional
review board.
Devices
Transcatheter aortic valve implantation was performed using the
Medtronic CoreValve ReValving System (CoreValve Inc., Irvine,
CA, USA; 26 and 29 mm; n = 13) and the second-generation,
balloon-expandable Edwards SAPIEN XT (Edwards Lifesciences
Inc., Irvine, CA, USA; 23–26 mm; n = 7). The Edwards prosthesis
was implanted via a transapical approach (n = 4) or a transfemoral
approach (n = 3). For the CoreValve System, a transfemoral ap-
proach was performed in all cases.
Computed tomographic data acquisition
All examinations were performed using a second-generation,
128-slice dual-source computed tomography (DSCT) system
(Somatom Deﬁnition Flash; Siemens Healthcare, Forchheim,
Germany). For the preoperative examination, ﬁrst 45 ml iopro-
mide (Ultravist 300, 300 mg/ml; Bayer Schering Pharma, Berlin,
Germany) was injected at a ﬂow rate of 5 ml/s, directly followed
by a second bolus of 35 ml at a ﬂow rate of 2.5 ml/s, followed by
60 ml bolus of saline solution at the same ﬂow rate. Bolus tracking
in the ascending aorta was performed with a signal-attenuation
threshold of 100 HU. A cranio-caudal scan direction was chosen
in all protocols. The scan ranged from the apex of the lung to the
symphysis. The CT scan was started automatically based on the
previous 10 heartbeats in order to reach the 60% R–R interval at
the level of the sinotubular junction. Postoperative ECG-gated
scans where performed with the same scan parameters in 15
patients. In ﬁve patients, postoperative native ECG-gated CT scans
ranging from the ascending aorta to the heart base were per-
formed due to reduced renal function. In addition, ex vivo native
DSCT examinations of the two different types of valve systems
imbedded in water were performed and their density values
evaluated.
Image analysis
Segmentation. For quantitative analysis, the centre line of the
aortic root and the ascending aorta was drawn semi-automatically
using dedicated software (3mensio benzslicer 4.3; Bilthoven,
Netherlands). The aortic annulus was deﬁned at the level of the
insertion of the leaﬂets (Fig. 1). Before and after the procedure,
the calciﬁcation of the aortic valve leaﬂets was segmented
semi-automatically separately for each cusp [left coronary (LC),
right coronary (RC) and non-coronary cusps (NC)]; derived from
these data, the volume and mass of the calciﬁcations were
analysed (Fig. 2). The attenuation value (HU), for each single voxel
within the segmented calciﬁcation was measured as a correlate to
the caliciﬁcation density.
Within the ex vivo devices, on three different levels three mea-
surements of the HU were performed. As all measurements of the
radiopaque stainless-steel material of the device were >2000 HU,
consecutively in the postprocedural CT data during segmentation
in the annulus plane, voxels of >2000 HU could be deﬁned as
device material and excluded (Fig. 2).
Distance measurements. The distances between the coronary
ostia, the left coronary ostium (LCO) and respectively the right
coronary ostium (RCO) to the neighbouring hightest and deepest
point of calciﬁcation of the valve leaﬂet were measured on all CT
scans (Fig. 3).
Figure 1: (A) Centre line of the aortic root and the ascending aorta. (B) and (C)
Anchor points at the level of the insertion of the aortic leaﬂets form the aortic
annulus.
T.D.L. Nguyen-Kim et al. / Interactive CardioVascular and Thoracic Surgery2
Statistical analysis
The mean value of HU of calciﬁcation for each cusp was calclu-
lated. The distribution was tested with the Kolmogorow–Smirnow
test. Given that a normal distribution was found for HU and the
distances, Student’s paired t-test was performed to compare pre-
and postprocedural values. Given that there was a non-normal
distribution for volume and mass, these values were correlated
using a Wilcoxon signed rank test. Relationships in changes
between mass, volume and HU were demonstrated by linear re-
gression analysis. Logistic regression analysis was used to show
potential correlations between the changes of mass, volume and
HU in correlation to the need for postoperative pacemaker im-
plantation. A change in mass, volume or HU of <5% was deﬁned
as stable, whereas an increase or decrease of >5% was deﬁned as
real dynamic change.
Postprocedural real calciﬁcation loss was deﬁned ﬁrst as a re-
duction of mass, volume and HU (scenario 1), second as a reduc-
tion of mass and volume but with stable HU (scenario 2) and third
as a reduction of mass and volumewith increasing HU (scenario 3).
Compression of calciﬁcation without its loss was deﬁned by as
stable mass, decrease of volume and increase of HU (scenario 4;
Table 1).
Continuous variables were expressed as means ± SD and cat-
egorical variables as frequencies or percentages. A P-value < 0.05
was considered as signiﬁcant. Linear regression analysis was per-
formed to assess correlations [17]. Statistical analysis was per-
formed using commercially available software (SPSS, release 19.0
for Windows; SPSS Inc., Chicago, IL, USA).
RESULTS
In all patients, the segmented calciﬁcation of the aortic valve
showed a signiﬁcant loss of calciﬁcation mass. The mean calciﬁca-
tion mass of the aortic valves measured before implantation was
258.5 ± 135.09 mg and after TAVI 173.33 ± 132.19 mg, translating
into a signiﬁcant decrease of calciﬁcation mass (P = 0.0007).
For all cusps—LC, RC and NC—signiﬁcantly lower postproce-
dural mean volumes and mean masses were found (P < 0.002 and
P < 0.001; Table 2). The mean differences in volume for NC, RC
and LC were −156.8 ± 53.7, −155.5 ± 62.5 and −115.0 ± 57.5 mm3,
respectively, and the differences in mass for NC, RC and LC were
−88.8 ± 29.5, −95.2 ± 39.3 and −71.6 ± 35.6 mg, respectively.
As a result of of AV block (grade III) in ﬁve cases and combined
total left bundle branch block and AV block grade I one case, six
Figure 2: (A) and (B) Measurements of volume and mass of valve calciﬁcations. (C) After native ex vivo and (D) native in vivo pixelprobes of the valve system, voxels
with a treshold attenuation over 2000 Hounsﬁel units were excluded.
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patients underwent pacemaker implantation after TAVI. Logistic
regression analysis comparing volume, mass and HU in the area of
the right coronary leaﬂet with the incidence of postoperative
pacemaker implantation showed no signiﬁcant correlation
(P = 0.24, P = 0.32 and P = 0.4, respectively).
In 80.0% of all cusps, a real loss of calciﬁcation was found. These
cusps are summarized in group 1. In 15% of all cusps, a compres-
sion of calciﬁcation without major calcium loss was seen, fulﬁlling
the criteria of scenario 4, and summarized in group 2. Within the
cusps in group 1, in 31.3% the criteria of scenario 1 (massive loss
of calciﬁcation) were seen, in 14.6% the criteria of scenario 2 and
in 56.5% of scenario 3. Unchanged parameters were seen in only
one cusp (1.7%). In another cusp (1.7%), mass and HU stayed
stable with a decrease of volume; while in a further cusp (1.7%), an
increase of mass and HU but a stable volume was found.
Figure 3: Distances between the left or right coronary ostium to the nearest neighbouring highest and deepest point of calciﬁcation of valve leaﬂet before and after
the procedure.
Table 2: Mean volumes, masses and Hounsfield units
before and after the procedure for each valve seperately
Preprocedure Postprocedure P-value
Mean ± SD volume (mm3)
NC 467.85 ± 83.96 311.05 ± 47.67 0.000019
RC 373.1 ± 78.63 217.56 ± 32.03 0.002
LC 336.56 ± 76.75 221.59 ± 32.83 0.00029
Mean ± SD mass (mg)
NC 313.23 ± 57.40 224.45 ± 37.81 0.00000017
RC 247.13 ± 51.72 151.93 ± 24.13 0.001
LC 215.16 ± 48.46 143.16 ± 22.20 0.00025
Mean ± SD Hounsfield units
NC 798.6 ± 105.7 849.17 ± 95.05 0.01
RC 786.2 ± 86.32 820.93 ± 69.57 0.126
LC 768.45 ± 86.39 785.79 ± 56.92 0.412
LC : left coronary cusp; RC: right coronary cusp; NC: non-coronary cusp.
Table 1: Postprocedural changes in mass, volume and
Hounsfield units
Scenario Mass Volume HU Group
Scenario 1 # # # Group 1
Scenario 2 # #  ! Group 1
Scenario 3 # # " Group 1
Scenario 4  ! # " Group 2
Group 1: loss of calcification; Group 2: compression of calcification;
HU: Hounsfield units; # = decrease; " = increase; ! = stable.
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For all cusps together, the mean HU was signiﬁcantly higher after
the procedure (mean HU before the procedure: 784.41 ± 11.9 HU;
after the procedure: 818.63 ± 10.3 HU; P < 0.004), which corrobo-
rates the theory of calciﬁcation compression after TAVI. With a focus
on each valve separately, a signiﬁcant change in mean HU was
found in the area of the non-coronary cusp (P = 0.01). For the left
coronary and right coronary cusps, no signiﬁcance was detected,
with P-values of P = 0.126 and P = 0.412, respectively (Table 2).
Regression analyses showed no signiﬁcant differences of volume,
mass and HU (P = 0.51, P = 0.38 and P = 0.26, respectively) compar-
ing the segmentations after implantation of the CoreValve System
and after implantation of the Edwards prosthesis. Regression ana-
lysis showed strong correlations between the pre- and postproce-
dural changes of volume and of mass, respectively, compared with
HU as a dependent variable (P < 0.0001, r = 0.88).
There were signiﬁcantly lower postprocedural mean distances
between LCO and RCO and their nearest neighbouring cranial
and caudal calciﬁcation points (P < 0.047; Table 3). Before the pro-
cedure, the mean distance between LCO and its next cranial calci-
ﬁcation was 9.7 ± 4 mm and after TAVI 4.8 ± 4 mm; for RCO, the
mean distance to its next cranial calciﬁcation was 10.1 ± 2.8 mm
before and 6.9 ± 3.2 mm after TAVI, resulting in 50.3% decrease in
calciﬁcation distance to LCO and 31.5% to RCO. In all patients,
there were no postprocedural cardiovascular complications
related to coronary impairment.
DISCUSSION
This study illustrates a loss of calciﬁcation in the area of the device
landing zone in all patients after TAVI. Correlating the three para-
meters mass, volume and HU (density), 80.0% of all cusps were
affected, as summarized in group 1 and analysed in the following
three scenarios (Table 1):
Scenario 1, a decrease of all three parameters—mass, volume and
calciﬁcation density—can be interpreted as surrogate for clear calciﬁ-
cation loss during the procedure with potential high embolic load;
Scenario 2, a decrease of mass and volume, but stable calciﬁca-
tion density, which may represent a smaller loss of calciﬁcation
(this can be considered as substantial calciﬁcation loss without any
sign of compression of the residual calciﬁcation); and
Scenario 3, a decrease of mass and volume, but an increase of
calciﬁcation density, which translates into a loss of calciﬁcation
with additional compression of the residual calciﬁcations.
In group 2, including 15% of all cusps, scenario 4 (Table 1) with
a postprocedural stable mass, a decrease of volume and an
increase of calciﬁcation density was observed, which can be
understood as a compression of calciﬁcation without loss.
Although we could see a compression of calciﬁcation and po-
tential pressure in the area of the aortic annulus, no signiﬁcant
correlation was found with the incidence of the postprocedural
need for pacemaker implantation. This can be explained by the
small number of patients included in this trial, which was not
powered for this end-point. In addition, in this speciﬁc cohort a
signiﬁcant change in calciﬁcation density was found only in the
area of the non-coronary cusp and not in the more sensitive
region of the right coronary cusp.
In only one cusp, before and after the procedure all parameters
were unchanged, either because the calciﬁcation was very strong
so that no compression or loss of calciﬁcation was possible or
because the surrounding tissue had enough elasticity to compen-
sate for the local mechanic changes induced during/after TAVI.
In one cusp, postprocedural mass and calciﬁcation density
remained stable with a decrease of volume, whereas in another
cusp the mass and calciﬁcation density increased with stable post-
procedural volume. This could be explained by periprocedural
partial dislocation of calciﬁcation to a neighbouring area within or
outside the cusp, so that it could not be measured or was add-
itionally captured in another cusp, which could equate to a ‘calciﬁ-
cation transfer’ during the procedure. Also, scattered error in
measurement could provide an explanation.
The signiﬁcant decrease of postprocederal mean distances
between LCO and RCO to their nearest neighbouring calciﬁcation is
an important ﬁnding that highlights the importance of preoperative
imaging for risk stratiﬁcation of potential coronary occlusion. These
changes verify the altered position of the leaﬂet and its calciﬁcation
after TAVI, which may lead to partial or complete obstruction of the
coronary ostium. In the study cohort, there was always a minimal
distance of 10 mm between the aortic annulus and the coronary
ostia in the CT scans, which again ensured an uncompromised
postoperative coronary ﬂow despite a signiﬁcant reduction in the
distances between calciﬁcations and coronary entries. Therefore,
no cardiovascular complications related to coronary obstruction
were encountered. Simulation of the calciﬁcation behaviour
during TAVI would be the next level of preoperative planning.
Although Webb et al. [18] showed a difference in the incidence
of stroke of 5.3% for the transfemoral approach and 1.8% for the
transapical approach, this could not be conﬁrmed in later studies.
Recent studies have reported a stroke rate after TAVI of 2.8–4.1%
[18, 19]. Rodés-Cabau showed a high rate of silent cerebral ischae-
mic lesions in diffusion-weighted magnetic resonance imaging,
ranging from 66 to 71%, with no differences between the transfe-
moral and transapical approaches. Recent studies showed an inci-
dence of acute kidney injury of 11.7–28.8% after TAVI [9, 10, 20].
The results of our study emphasize the risk of calciﬁcation loss
after TAVI and a potential relationship to the high rate of silent
cerebral ischaemic lesions in diffusion-weighted magnetic reson-
ance imaging, as well as to the known high incidence of cerebro-
vascular complications, with no difference for either approach [7].
Given that the manipulation and the displacement of the stenosed
and rigid native leaﬂets by implantation of the stent frame is
similar for both transfemoral and transapical approaches, the
resulting dislodgement of calciﬁcation debris from the valve itself
can be also considered similar.
Owing to the proven likelihood of calciﬁcation loss after
TAVI and the known embolic ischaemic cerebral lesions, the de-
velopment of protective shields to reduce the risk of cerebrovas-
cular complications is currently underway. Although about 72.7–
Table 3: Distances to left coronary ostium (LCO) and right
coronary ostium (RCO) to its next most cranial or caudal
calcification of leaflet
Prepocedure Postprocedure P-value
Mean distance ± SD to most cranial calcification of leaflet (mm)
LCO 9.66 ± 3.96 4.8 ± 3.90 0.00008
RCO 10.11 ± 2.82 6.93 ± 4.17 0.006
Mean ± SD distance to most caudal calcification of leaflet (mm)
LCO 13.86 ± 5.56 10.03 ± 5.55 0.0003
RCO 15.62 ± 3.06 13.21 ± 4.18 0.047
LC: left coronary ostium; RC: right coronary ostium.
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84% of cerebral embolisms after TAVI are clinically silent, this does
not rule out long-term cognitive impairment. Different concepts
of protective devices are already available but not in routine
clinical use; The Claret device (Claret Medical, Inc., Santa Rosa,
CA, USA) or the Embrella Embolic Deﬂector System (Embrella
Cardiovascular, Inc., Wayne, PA, USA) can be placed in the aortic
arch to avoid embolic lesions [21, 22]. In a study of ﬁrst-in-man
use of the Claret device, although not systematically evaluated,
Naber et al. could demonstrate using photographic techniques
the macroscopic incidence of debris in individuals [23].
There are some limitations to the study, such as the small
number of patients in our cohort. Although a signiﬁcant loss of
calciﬁcation was demonstrated in all patients after TAVI, as well as
a decrease of calciﬁcation distances to the coronary ostia, no cor-
relation with any postprocedural symptomatic complications
could be found. However, silent cerebral lesions have been found
after TAVI [7]; therefore, further studies are needed to deﬁne any
risk stratiﬁcation. Owing to preoperative planning, no native CT
scans were performed, but contrast-enhanced CT-scans were
carried out for additional evaluation of the peripheral vascular
status. Cademartiri et al. [24] have shown that intraluminal en-
hancement signiﬁcantly inﬂuences the non-calciﬁed plaque
density, but does not signiﬁcantly alter the calciﬁed plaques.
Partial volume and interpolation can particularly affect neighbour-
ing voxels, because higher attenuation of the device is associated
with a higher range of densities in the neighbouring calciﬁcation
[24]. To reduce the error within the segmented calciﬁcations, a
change in HU of <5% was deﬁned as stable, and an increase or de-
crease of >5% was deﬁned as real dynamic change.
As TAVI is a rapidly evolving technique that may become a true
alternative to conventional AVR, especially in younger patients
with lower risk proﬁles, further studies are needed with larger
numbers of patients, powered for meaningful clinical outcomes.
This may lead to a better understanding of the dynamic changes
of mass, volume and calciﬁcation density during the procedure.
Conclusion
In conclusion, we could demonstrate a signiﬁcant loss of calciﬁca-
tion in all patients after TAVI, as well as a reduction of calciﬁcation
distances to the coronary ostia. Further studies are needed to
assess the potential clinical evidence of additional protective tech-
niques and devices during TAVI procedures.
Conﬂict of interest: none declared.
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